Short Interest in Aquestive Therapeutics, Inc. (NASDAQ:AQST) Declines By 6.0%

Aquestive Therapeutics, Inc. (NASDAQ:AQST) saw a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 10,140,000 shares, a decline of 6.0% from the October 15th total of 10,790,000 shares. Based on an average daily volume of 1,340,000 shares, the days-to-cover ratio is presently 7.6 days.

Aquestive Therapeutics Stock Up 3.9 %

NASDAQ AQST opened at $4.82 on Wednesday. Aquestive Therapeutics has a 52 week low of $1.73 and a 52 week high of $6.23. The business has a 50 day moving average price of $4.99 and a 200-day moving average price of $3.89. The company has a market cap of $439.49 million, a price-to-earnings ratio of -10.71 and a beta of 2.82.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The business had revenue of $13.54 million for the quarter, compared to analyst estimates of $12.69 million. During the same period in the previous year, the business earned ($0.03) EPS. On average, equities research analysts anticipate that Aquestive Therapeutics will post -0.47 earnings per share for the current year.

Institutional Investors Weigh In On Aquestive Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in AQST. Vanguard Group Inc. boosted its stake in Aquestive Therapeutics by 71.7% during the 1st quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company’s stock valued at $13,813,000 after purchasing an additional 1,353,518 shares during the last quarter. State Street Corp boosted its position in shares of Aquestive Therapeutics by 52.1% during the third quarter. State Street Corp now owns 1,496,739 shares of the company’s stock valued at $7,454,000 after buying an additional 512,682 shares during the last quarter. Blue Owl Capital Holdings LP grew its holdings in Aquestive Therapeutics by 30.3% during the second quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock worth $2,964,000 after buying an additional 265,000 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in Aquestive Therapeutics in the 2nd quarter valued at $594,000. Finally, Verition Fund Management LLC bought a new position in Aquestive Therapeutics during the 3rd quarter valued at $995,000. 32.45% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

AQST has been the subject of several recent analyst reports. Leerink Partners raised their target price on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research report on Wednesday, November 6th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $9.80.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.